Seems unlikely that two unconnected editors have singular interests in Catalent and ImClone Systems. In fact both seem to be drawn almost entirely to edits on pharmaceutical companies which mirror company announcements, e.g. "FDA approval on migraine treatment drug" and "Catabasis announces underwritten public offering". Additional behavior:
Signed here ☆ Bri ( talk) 23:24, 20 April 2020 (UTC)
If this checks out, there's another less pharma-centric user who uses "copy" in their edit summary. ☆ Bri ( talk) 00:14, 21 April 2020 (UTC)
Accused parties may also comment/discuss in this section below. See Defending yourself against claims.
Seems unlikely that two unconnected editors have singular interests in Catalent and ImClone Systems. In fact both seem to be drawn almost entirely to edits on pharmaceutical companies which mirror company announcements, e.g. "FDA approval on migraine treatment drug" and "Catabasis announces underwritten public offering". Additional behavior:
Signed here ☆ Bri ( talk) 23:24, 20 April 2020 (UTC)
If this checks out, there's another less pharma-centric user who uses "copy" in their edit summary. ☆ Bri ( talk) 00:14, 21 April 2020 (UTC)
Accused parties may also comment/discuss in this section below. See Defending yourself against claims.